Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EPS (Basic) (2016 - 2025)

Neurocrine Biosciences' EPS (Basic) history spans 16 years, with the latest figure at $1.54 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 49.51% year-over-year to $1.54; the TTM value through Dec 2025 reached $4.82, up 42.6%, while the annual FY2025 figure was $4.81, 41.47% up from the prior year.
  • EPS (Basic) reached $1.54 in Q4 2025 per NBIX's latest filing, down from $2.11 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $2.11 in Q3 2025 to a low of -$0.79 in Q1 2023.
  • Average EPS (Basic) over 5 years is $0.67, with a median of $0.68 recorded in 2024.
  • Peak YoY movement for EPS (Basic): soared 1250.0% in 2022, then plummeted 626.67% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.08 in 2021, then skyrocketed by 1250.0% to $0.92 in 2022, then soared by 64.13% to $1.51 in 2023, then tumbled by 31.79% to $1.03 in 2024, then surged by 49.51% to $1.54 in 2025.
  • Per Business Quant, the three most recent readings for NBIX's EPS (Basic) are $1.54 (Q4 2025), $2.11 (Q3 2025), and $1.09 (Q2 2025).